Table 2.
Characteristics of the study population (n = 94).
| Age, median (range), years | 63 (42–79) |
| Parity, median (range) yrs | 2 (0–6) |
| Comorbidities | |
| Diabetes | 24 |
| Hypertension | 14 |
| Obesity (BMI >30) | 06 |
| Hypothyroidism | 03 |
| IHD on drug-eluting stent | 01 |
| Multiple myeloma | 01 |
| Carcinoma breast on tamoxifen | 03 |
| Symptomatology | |
| Postmenopausal bleeding | 76 |
| Postmenopausal discharge PV | 04 |
| Carcinoma breast post treatment follow up with abnormal ET | 02 |
| Heavy menstrual bleeding | 06 |
| Irregular bleeding | 02 |
| Abdominal distension | 01 |
| Abnormal cells on PAP | 01 |
| Method of biopsy | |
| Pipelle biopsy | 22 |
| OPD EB | 54 |
| Hysteroscopy + biopsy | 14 |
| D&C/FC | 04 |
EB, endometrial biopsy; BMI, body mass index. IHD, Ischemic Heart disease; PV, Per vaginum; ET, Endometrial Thickness; PAP, Papanicoloau Smear; OPD, Out Patient Department; D&C, Dilatation & Curettage; FC, Fractional Curettage.